中国中西医结合杂志2025，Vol.45Issue(6)：684-691,8.DOI:10.7661/j.cjim.20250507.009
龙柴降血方治疗真性红细胞增多症疗效观察及优势人群分析
Longchai Jiangxue Formula in Polycythemia Vera:Therapeutic Efficacy and Identification of Optimal Responders
摘要
Abstract
Objective To evaluate the therapeutic efficacy of Longchai Jiangxue Formula(LCJX)in polycythemia vera(PV)patients and identify optimal responder subpopulations.Methods Eighty PV patients were allocated into control(33 cases)and experimental(47 cases)groups based on their preference.Both groups received conventional treatment.The experimental group received LCJX additionally.Both groups underwent 4 months of treatment.Baseline characteristics and cytoreductive drug usage were analyzed between the two groups.Post treatment outcomes included the response rate,blood cell counts,MPN-10 scores,thrombosis and bleeding events,and disease progression between the 2 groups.The adverse reactions during treatment were recorded.The optimal responder population for LCJX in PV was analyzed.Results Thirty control and 42 experimental patients completed the study,and were included in the statistical analysis.No differences were observed in baseline characteristics and cytoreductive drug usage(P＞0.05).The experimental group exhibited a higher response rate than the control group(83.3％vs.60.0％,P＜0.05).Compared with the control group,post-treatment,the levels of hematocrit(HCT),hemoglobin(HGB),blood platelet(PLT)were decreased in the experimental group(P＜0.05);the MPN-10 total scores and the symptom scores of fatigue,abdominal discomfort,inactivity,night sweats,and itching were all declined in the experimental group(P＜0.05).No thrombosis,bleeding events,or disease progression occurred in either group.No significant difference in the incidence rate of adverse reactions was observed between the two groups(36.7％vs.28.5％,P＞0.05).Patients with JAK2 mutation burden ≥ 60％(OR 4.722,95％CI:1.068-20.887)or the total score of MPN-10≥ 15 points were the optimal responder population for LCJX in PV(OR 4.200,95％CI:1.054-16.738).Conclusions LCJX can increase the response rate,decrease blood cell counts,and alleviate PV-related symptoms,particularly in patients with JAK2 mutation burden ≥ 60％or MPN-10 total score ≥ 15 points.LCJX is proven to be effective and safe in the treatment of PV.(Chinese Clinical Trial Registry No.ChiCTR2200057736).关键词
真性红细胞增多症/龙柴降血方/中药复方/有效率/血细胞计数/优势人群/中西医结合Key words
polycythemia vera/Longchai Jiangxue Formula/Chinese herbal compound/response rate/blood cell count/optimal responders/integrative medicine引用本文复制引用
罗璠,王子卿,王德好,张延宇,余心悦,王明镜,刘为易,吕妍,胡晓梅..龙柴降血方治疗真性红细胞增多症疗效观察及优势人群分析[J].中国中西医结合杂志,2025,45(6):684-691,8.基金项目
国家自然科学基金面上项目(No.82174360) （No.82174360）
中国中医科学院科技创新工程重点协同攻关项目(No.CI2023C027YL) （No.CI2023C027YL）
中国中医科学院科技创新工程重大攻关项目(No.CI2021A01702) （No.CI2021A01702）
